Close
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Jun 1, 2024 08:10AM

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study

Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years

TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC

NEW YORK--(BUSINESS... (continue reading...)


Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 Jun 1, 2024 08:05AM

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors

With approximately two years of median follow-up, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months

DUBLIN, June 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced... (continue reading...)


Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting Jun 1, 2024 08:05AM

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in... (continue reading...)


Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA Jun 1, 2024 08:00AM

Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial

HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024

Conference Call to be Held at 8:00am ET on Monday, June 3, 2024

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a... (continue reading...)


Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse Jun 1, 2024 08:00AM

BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by alpaca IGH-VDJ genes in-situ.

In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered.... (continue reading...)


More Press Releases

View Older Stories

Jun 1, 2024 08:00AM James Avery Artisan Jewelry Opens New Store at Westover Marketplace
Jun 1, 2024 08:00AM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Jun 1, 2024 08:00AM TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Jun 1, 2024 08:00AM Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Jun 1, 2024 08:00AM Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jun 1, 2024 08:00AM Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Jun 1, 2024 08:00AM BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
Jun 1, 2024 08:00AM Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
Jun 1, 2024 08:00AM KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
Jun 1, 2024 08:00AM Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
Jun 1, 2024 08:00AM OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
Jun 1, 2024 08:00AM Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Jun 1, 2024 08:00AM Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Jun 1, 2024 08:00AM Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Jun 1, 2024 08:00AM CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
Jun 1, 2024 08:00AM Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Jun 1, 2024 08:00AM Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Jun 1, 2024 07:55AM ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jun 1, 2024 08:15AM Gruvtype features de Buyer Products in Global Culinary Adventure with Free "Street, Beach & Sky" Preview Cookbook
Jun 1, 2024 07:10AM Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo
Jun 1, 2024 07:00AM Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Jun 1, 2024 07:38AM Horizon Wealth Donates $3 Million for Brazil's Post-Disaster Reconstruction
Jun 1, 2024 07:38AM Eurasian Capital Participates in the Third ICPAC Mediterranean Financial Summit: Exploring the Future Frontiers of Finance
Jun 1, 2024 06:20AM XAR and Salus Join Forces to Build zkLogin 'Hikari': The Final Step to Mass Adoption on Starknet
Jun 1, 2024 07:05AM Brandmydispo Continues to Innovate the Custom Mylar Bag Space
Jun 1, 2024 05:55AM ZEEKR Announces May 2024 Delivery Update
Jun 1, 2024 06:43AM Pamela Dowell's newly released "Saucey's Adventure" is a delightful adventure of a young unicorn in an unknown land.
Jun 1, 2024 05:42AM VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
Jun 1, 2024 05:41AM SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
Jun 1, 2024 05:39AM SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
Jun 1, 2024 05:37AM PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
Jun 1, 2024 05:36AM CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
Jun 1, 2024 05:34AM CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
Jun 1, 2024 05:33AM BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
Jun 1, 2024 05:30AM NIO Inc. Provides May 2024 Delivery Update
Jun 1, 2024 05:00AM XPENG Announces Vehicle Delivery Results for May 2024
Jun 1, 2024 03:23AM Subsea7 awarded four PLSV contracts in Brazil
Jun 1, 2024 03:00AM Swiss Properties Invest has finalised the acquisition of an attractive commercial property in Koblenz in the Canton of Aargau
Jun 1, 2024 02:43AM Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
Jun 1, 2024 02:28AM ALL-TIME BEST MONTHLY SALES FOR THE KIA EV9 AND SPORTAGE SUVs LEAD KIA AMERICA TO SECOND BEST SALES MONTH IN COMPANY HISTORY IN MAY
Jun 1, 2024 02:00AM 'A Fu, the hutong gentleman'
Jun 1, 2024 01:46AM HTX Ventures Invests in Babylon to Advance Trustless Bitcoin Staking
Jun 1, 2024 12:30AM Pink Curing Salt: SPQR Seasonings Becomes Best-Selling #1 Brand On Amazon.com
Jun 1, 2024 12:27AM VTRConnect Launches Real Estate Mega App
Jun 1, 2024 12:00AM Flash News: OKX Lists WLD/USDC Spot Trading Pair
May 31, 2024 11:13PM AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
May 31, 2024 10:06PM Unigold Announces Extension of Non-Brokered Private Placement of up to $2,000,000
May 31, 2024 10:02PM The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
May 31, 2024 10:00PM Skymizer Launches Groundbreaking LLM Accelerator IP for on-device LLM Inferencing, EdgeThought, the game-changer in on-device GenAI era.
May 31, 2024 10:00PM Li Auto Inc. May 2024 Delivery Update
View Older Stories